BRPI0418756A - composições e métodos para inibir a reabsorção óssea - Google Patents
composições e métodos para inibir a reabsorção ósseaInfo
- Publication number
- BRPI0418756A BRPI0418756A BRPI0418756-3A BRPI0418756A BRPI0418756A BR PI0418756 A BRPI0418756 A BR PI0418756A BR PI0418756 A BRPI0418756 A BR PI0418756A BR PI0418756 A BRPI0418756 A BR PI0418756A
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- vitamin
- inhibiting
- bone resorption
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 5
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 208000006386 Bone Resorption Diseases 0.000 title abstract 2
- 230000024279 bone resorption Effects 0.000 title abstract 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 3
- 229930003316 Vitamin D Natural products 0.000 abstract 2
- 235000019166 vitamin D Nutrition 0.000 abstract 2
- 239000011710 vitamin D Substances 0.000 abstract 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 2
- 229940046008 vitamin d Drugs 0.000 abstract 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 208000013038 Hypocalcemia Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 229940062527 alendronate Drugs 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 230000037058 blood plasma level Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000018678 bone mineralization Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000705 hypocalcaemia Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000035764 nutrition Effects 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 235000005282 vitamin D3 Nutrition 0.000 abstract 1
- 239000011647 vitamin D3 Substances 0.000 abstract 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 1
- 229940021056 vitamin d3 Drugs 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSIçõES E MéTODOS PARA INIBIR A REABSORçãO õSSEA". As composições e métodos são descritos para prevenir, inibir, reduzir e tratar condições e doenças associadas com reabsorção óssea anormal em mamíferos, incluindo por exemplo, osteoporose. Modalidades de composições da invenção compreendem uma quantidade farmaceuticamente eficaz de alendronato e vitamina D3 adequada para dosagem uma vez por semana. As composições e métodos da invenção fornecem nutrição de vitamina D durante o tratamento com bisfosfonato para facilitar a formação óssea normal e mineralização ao minimizar a ocorrência de ou potencial para as complicações associadas com insuficiência de vitamina D, tal como hipocalcaemia e osteomalacia. Da mesma forma descritos, são os métodos para fabricar composições da presente invenção, para medir a estabilidade e degradação dessas composições, e para medir os níveis de plasma sanguíneo de vitamina D.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/015743 WO2005117906A1 (en) | 2004-05-19 | 2004-05-19 | Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0418756A true BRPI0418756A (pt) | 2007-09-11 |
Family
ID=34958686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0418756-3A BRPI0418756A (pt) | 2004-05-19 | 2004-05-19 | composições e métodos para inibir a reabsorção óssea |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1758594A1 (pt) |
| CN (1) | CN1993134A (pt) |
| BR (1) | BRPI0418756A (pt) |
| WO (1) | WO2005117906A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745226B2 (en) | 2005-04-06 | 2010-06-29 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites |
| KR100822133B1 (ko) * | 2006-11-06 | 2008-04-15 | 한미약품 주식회사 | 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제 |
| JP2010513475A (ja) * | 2006-12-20 | 2010-04-30 | ランドシュタイナー サイエンティフィック エッセ アー デ シー ヴイ | リセドロネートおよびビタミンｄ組成物 |
| EP2124963A4 (en) * | 2006-12-20 | 2010-03-17 | Mylan Pharmaceuticals Ulc | COMPOSITION WITH A BISPHOSPHONIC ACID IN COMBINATION WITH VITAMIN D |
| CN101444521B (zh) * | 2007-11-26 | 2012-07-04 | 信谊药厂 | 包含阿仑膦酸钠和胆维丁的药物制剂 |
| US7972868B2 (en) | 2007-11-28 | 2011-07-05 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry |
| KR101102364B1 (ko) * | 2009-09-18 | 2012-01-03 | 한림제약(주) | 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물 |
| US7977117B2 (en) | 2009-12-03 | 2011-07-12 | Quest Diagnostics Investments Incorprated | Vitamin D metabolite determination utilizing mass spectrometry following derivatization |
| JP6113504B2 (ja) | 2009-12-11 | 2017-04-12 | クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド | 非誘導体化非代謝化ビタミンｄの質量分析法による決定 |
| US9034653B2 (en) | 2009-12-11 | 2015-05-19 | Quest Diagnostics Investments Inc. | Mass spectrometry of steroidal compounds in multiplexed patient samples |
| CN102210697B (zh) * | 2010-04-02 | 2013-05-22 | 秦引林 | 用于治疗代谢性骨病的药物组合 |
| KR101230178B1 (ko) * | 2010-06-10 | 2013-02-06 | 주식회사 네비팜 | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| EP3867650A1 (en) * | 2018-10-18 | 2021-08-25 | Fresenius Medical Care Holdings, Inc. | Techniques for modeling parathyroid gland functionality and calcimimetic drug activity |
| EP4593867A2 (en) | 2022-09-30 | 2025-08-06 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
| CN116082536B (zh) * | 2023-02-16 | 2024-04-26 | 广州汇元医药科技有限公司 | 具有骨靶向功能的聚合物及其制备方法和用途、纳米载体及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0753523A1 (en) * | 1995-07-10 | 1997-01-15 | Gador S.A. | Amino-substituted bisphosphonic acids |
| AR013994A1 (es) * | 1998-10-30 | 2001-01-31 | Gador Sa | Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes. |
| FR2814369B1 (fr) * | 2000-09-27 | 2004-05-21 | Spmd | Preparation medicamenteuse a base de vitamines d3 et son procede de fabrication |
| WO2003007916A1 (en) * | 2001-07-17 | 2003-01-30 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| AU2003226148A1 (en) * | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| CA2497353C (en) * | 2002-09-16 | 2012-08-28 | Novartis Ag | Method for preventing or reducing secondary fractures after hip fracture |
-
2004
- 2004-05-19 BR BRPI0418756-3A patent/BRPI0418756A/pt not_active Application Discontinuation
- 2004-05-19 CN CNA2004800436180A patent/CN1993134A/zh active Pending
- 2004-05-19 EP EP04776045A patent/EP1758594A1/en not_active Withdrawn
- 2004-05-19 WO PCT/US2004/015743 patent/WO2005117906A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN1993134A (zh) | 2007-07-04 |
| EP1758594A1 (en) | 2007-03-07 |
| WO2005117906A1 (en) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0518315A2 (pt) | compostos de tiazol que modulam a atividade da proteÍna hsp90, mÉtodos de inibiÇço, tratamento e induÇço associados e composiÇço farmacÊutica | |
| WO2009039175A3 (en) | Method for inhibiting bone resorption | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| PT721501E (pt) | Composicao farmaceutica que compreende fosfatase ou um seu derivado | |
| BR112022005059A2 (pt) | Composições para tratamento bucal com atividade anticárie | |
| JP2010525080A5 (pt) | ||
| RU2014127746A (ru) | Композиция, содержащая ингибирующие кристаллизацию вещества | |
| GB2487712A8 (en) | use of the phtocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy | |
| AU2003256755A8 (en) | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations | |
| BR112015022538A2 (pt) | terapia de indução de rituximab seguida por terapia de acetato de glatirâmero | |
| WO2009137465A3 (en) | Compositions for treatment or prevention of pathological cardiac remodeling and heart failure | |
| MX2009002924A (es) | Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos. | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BR0309623A (pt) | Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas | |
| MX2010007242A (es) | Composiciones farmaceuticas que comprenden granulos de lipasa microbiana purificada y metodos para prevenir o tratar trastornos digestivos. | |
| PH12014500558A1 (en) | Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease | |
| MX2009006768A (es) | Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes. | |
| MX2010001847A (es) | Derivados de n-bencil, n'-arilcarbonilpiperazina en la forma de moduladores lxr. | |
| BR112012005837A8 (pt) | Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| SG10201406846XA (en) | Bisphosphonate compounds for treating bone metabolism disorders | |
| WO2012112677A3 (en) | Methods for treating lysosomal acid lipase deficiency | |
| BRPI0512503A (pt) | composição que compreende ácido lático e lactoferrina | |
| BRPI0514397A (pt) | derivados de 3-ariltioindol-2-carboxamida e análogos destes como inibidores de caseìna cinase iépsilon | |
| TW200616644A (en) | Medicine for prevention or treatment of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |